FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)

被引：0
|
作者：
Moore, K. [1 ]
Oza, A. [2 ]
Colombo, N. [3 ,4 ]
Oaknin, A. [5 ]
Scambia, G. [6 ]
Lorusso, D. [7 ]
Farias-Eisner, R. [8 ]
Banerjee, S. [9 ]
Murphy, C. [10 ]
Tanyi, J. [11 ]
Hirte, H. [12 ]
Konner, J. [13 ]
Lim, P. [14 ]
Hayes, M. Prasad [15 ]
Monk, B. [16 ]
Kim, S. [17 ]
Wang, J. [18 ]
Pautier, P. [19 ]
Vergote, I. [20 ]
Birrer, M. [21 ]
机构：
[1] Univ Oklahoma, Dept Obstet & Gynecol Univ, Stephenson Canc Ctr, Oklahoma City, OK USA
[2] Univ Hlth Network, Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
[3] European Inst Oncol, Dept Gynecol Oncol, Milan, Italy
[4] Univ Milano Bicocca, Milan, Italy
[5] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain
[6] Univ Cattolica, Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy
[7] Fdn IRCCS Ist Nazl Tumori, Gynecol Oncol, Milan, Italy
[8] Univ Calif Los Angeles, Dept Obstet & Gynecol, Los Angeles, CA 90024 USA
[9] Royal Marsden Hosp NHS Fdn Trust, Gynaecol, London, England
[10] Bon Secours Hosp, Med Oncol, Cork, Ireland
[11] Univ Penn, Obstet & Gynecol, Philadelphia, PA 19104 USA
[12] Juravinski Canc Ctr, Oncol, Hamilton, ON, Canada
[13] Mem Sloan Kettering Canc Ctr, Gynecol Oncol, 1275 York Ave, New York, NY 10021 USA
[14] Ctr Hope, Gynecol Oncol, Reno, NV USA
[15] Icahn Sch Med Mt Sinai, Obstet & Gynecol, New York, NY 10029 USA
[16] Creighton Univ, Univ Arizona, St Josephs Hosp, Gynecol Oncol,Arizona Oncol,Coll Med,Sch Med, Phoenix, AZ USA
[17] Univ Texas Houston, McGovern Med Sch, Houston, TX USA
[18] ImmunoGen Inc, Clin Dev, Waltham, MA USA
[19] Gustave Roussy, Med, Villejuif, France
[20] Univ Hosp Leuven Campus Gasthuisberg, Gynaecol, Leuven, Belgium
[21] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, MA USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
992O
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
    Weekes, Colin D.
    Lamberts, Laetitia E.
    Borad, Mitesh J.
    Voortman, Johannes
    McWilliams, Robert R.
    Diamond, Jennifer R.
    de Vries, Elisabeth G. E.
    Verheul, Henk M.
    Lieu, Christopher H.
    Kim, George P.
    Wang, Yulei
    Scales, Suzie J.
    Samineni, Divya
    Brunstein, Flavia
    Choi, YounJeong
    Maslyar, Daniel J.
    Colon-Otero, Gerardo
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (03) : 439 - 447
  • [32] Phase 3 MIRASOL (GOG 3045/ENGOT-ov55) Trial: Mirvetuximab Soravtansine (MIRV) Prolongs Overall Survival vs Investigator's Choice Chemotherapy (IC) in Platinum-Resistant Ovarian Cancer (PROC) with High Folate Receptor-Alpha (FRa) Expression
    Hilpert, Felix
    Harter, Philipp
    Lorusso, Domenica
    Konecny, Gottfried. E.
    Banerjee, Susana
    Colombo, Nicoletta
    Wang, Yuemei
    Stec, James
    Method, Michael
    Van Gorp, Toon
    Moore, Kathleen
    de Gregorio, Nikolaus
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 91 - 91
  • [33] Initial results from a first-in-human study of AZD5335, a folate receptor a (FRa)-targeted antibody-drug conjugate, in patients (pts) with platinum-resistant recurrent ovarian cancer (PRROC)
    Shapira-Frommer, R.
    Sudo, K.
    Harano, K.
    Mileshkin, L.
    Perets, R.
    Song, M.
    Cohen, J.
    Huang, Y-F.
    Ambrose, H.
    Brier, T.
    Dosani, A.
    Fraenkel, P. G.
    Kmieciak, A.
    Mitchell, P.
    Myers, C.
    Wang, J.
    Odegbami, R. I.
    Sykes, A.
    Turner, S.
    Meric-Bernstam, F.
    ANNALS OF ONCOLOGY, 2024, 35 : S572 - S573
  • [34] Targeting MUC16 with the antibody-drug conjugate (ADC) DMUC5754A in patients with platinum-resistant ovarian cancer: A phase I study of safety and pharmacokinetics.
    Liu, Joyce
    Moore, Kathleen
    Birrer, Michael
    Berlin, Suzanne
    Matulonis, Ursula
    Infante, Jeffrey
    Xi, Jian
    Kahn, Robert
    Wang, Yulei
    Wood, Katie
    Coleman, Daniel
    Maslyar, Daniel
    Humke, Eric
    Burris, Howard
    CANCER RESEARCH, 2013, 73 (08)
  • [35] Phase 1 Dose-Escalation Study of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor α-Targeting Antibody-Drug Conjugate, in Patients With Solid Tumors
    Moore, Kathleen N.
    Borghaei, Hossein
    O'Malley, David M.
    Jeong, Woondong
    Seward, Shelly M.
    Bauer, Todd M.
    Perez, Raymond P.
    Matulonis, Ursula A.
    Running, Kelli L.
    Zhang, Xiaoyan
    Ponte, Jose F.
    Ruiz-Soto, Rodrigo
    Birrer, Michael J.
    CANCER, 2017, 123 (16) : 3080 - 3087
  • [36] Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study.
    Matulonis, Ursula A.
    Oaknin, Ana
    Pignata, Sandro
    Denys, Hannelore
    Colombo, Nicoletta
    Van Gorp, Toon
    Konner, Jason A.
    Romeo, Marga
    Harter, Philipp
    Murphy, Conleth G.
    Wang, Jiuzhou
    Method, Michael W.
    Esteves, Brooke
    Coleman, Robert L.
    Lorusso, Domenica
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] Phase 1 study of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors.
    Borghaei, Hossein
    O'Malley, David M.
    Seward, Shelly Marie
    Bauer, Todd Michael
    Perez, Raymond P.
    Oza, Amit M.
    Jeong, Woondong
    Michenzie, Mary F.
    Kirby, Maurice William
    Chandorkar, Gurudatt
    Ruiz-Soto, Rodrigo
    Birrer, Michael J.
    Moore, Kathleen N.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] Safety findings from FORWARD II: A Phase 1b study evaluating the folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovarian cancer.
    O'Malley, David M.
    Moore, Kathleen N.
    Vergote, Ignace
    Martin, Lainie P.
    Gilbert, Lucy
    Martin, Antonio Gonzalez
    Nepert, Dale L.
    Ruiz-Soto, Rodrigo
    Birrer, Michael J.
    Matulonis, Ursula A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [39] Phase 3 MIRASOL (GOG 3045/ENGOT-ov55) trial: Mirvetuximab soravtansine (MIRV) vs. investigator's choice chemotherapy (ICC) in older patients with platinum-resistant ovarian cancer (PROC) and high folate receptor-alpha (FRα) expression
    Bello, Diana
    Van Gorp, Toon
    Konecny, Gottfried E.
    Estevez-Garcia, Purificacion
    Moroney, John William
    Banerjee, Susana N.
    Myers, Tashanna K. N.
    Zamagni, Claudio
    Parma, Gabriella
    Sonnenburg, DanielW
    Roszak, Andrzej
    Lalisang, Roy Iqbal
    Shapira-Frommer, Ronnie
    Klat, Jaroslav
    Wang, Yuemei
    Method, Michael W.
    Moore, Kathleen N.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models1
    Ponte, Jose F.
    Ab, Olga
    Lanieri, Leanne
    Lee, Jenny
    Coccia, Jennifer
    Bartle, Laura M.
    Themeles, Marian
    Zhou, Yinghui
    Pinkas, Jan
    Ruiz-Soto, Rodrigo
    NEOPLASIA, 2016, 18 (12): : 775 - 784
12345